Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 9/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | STK17B | O94768 | 1/20 | 0.33 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22551859 | 0.81 | ADORA2A (0.50) | MAPKAPK2ATR | |
| SCHEMBL22579093 | 0.76 | MAPKAPK2 (0.48) | MAPKAPK2ATR | |
| SCHEMBL21722462 | 0.67 | ADORA2A (0.55) | ATR | |
| SCHEMBL11927607 | 0.66 | MAPKAPK2 (0.57) | MAPKAPK2 | |
| SCHEMBL16532758 | 0.65 | GAA (0.48) | KDM4AGRM2CACNA1HCACNA1BCACNA1C | |
| SCHEMBL6468245 | 0.64 | KDM4A (0.42) | MAPKAPK2KDM4ACYP1A2CACNA1HCACNA1B | |
| SCHEMBL122455 | 0.64 | GAA (0.42) | KDM4AIDO1STK17BSTK17A | |
| SCHEMBL24423243 | 0.64 | STK17B (0.50) | MAPKAPK2KDM4AATRIDO1STK17B | |
| SCHEMBL2004242 | 0.64 | TSHR (0.44) | KDM4AGRM2IDO1 | |
| SCHEMBL19782553 | 0.64 | ATR (0.47) | MAPKAPK2KDM4AATRSTK17BSTK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115181092-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-10898481-B2 | Pyrazine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-26 | — | — | US | disclosed |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10898481-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | MAPKAPK2 1351/4885KDM4A 4319/4885ATR 2808/4885 |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | MAPKAPK2 1351/4885KDM4A 4319/4885ATR 2808/4885 |
| US-11571420-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | MAPKAPK2 1351/4885KDM4A 4319/4885ATR 2808/4885 |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | MAPKAPK2 1351/4885KDM4A 4319/4885ATR 2808/4885 |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | MAPKAPK2 1351/4885KDM4A 4319/4885ATR 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.